의약품 제조 시장 규모, 점유율 및 동향 분석 보고서 : 투여 경로별, 분자별, 의약품 개발 단계별, 판매 채널별, 치료 영역별, 처방별, 지역별 및 부문별 예측(2026-2033년)

The global pharmaceutical manufacturing market size was valued at USD 616.1 billion in 2025 and is projected to grow from USD 664.0 billion in 2026 to USD 990.5 billion in 2033, at a CAGR of 5.8% from 2026 to 2033. North America dominated the market, accounting for a revenue share of 40.2% in 2025. The market is driven by demand for advanced therapeutics, biologics, and high-volume generic drugs alongside increasing chronic disease prevalence and healthcare spending.

With more patients and advanced treatments, demand for both traditional drugs and complex biologics has been increasing significantly. This has stimulated production scale ups and capacity enhancements among manufacturers, while ensuring consistent quality, safety, and compliance with regulatory frameworks. The increasing number of drug approvals by regulatory bodies is also expected to drive growth in drug manufacturing processes. In 2025, the FDA approved 32 novel drugs, indicating a positive trend.

A major driver supporting the market is the rapid evolution of drug development technologies. Increasing adoption of biologics, biosimilars, cell and gene therapies, and personalized medicines is reshaping production requirements, prompting manufacturers to invest in flexible, high-precision bioprocessing systems. At the same time, the shift toward continuous manufacturing and automation is helping companies reduce operational costs, optimize output, and improve product reliability, all of which are essential for meeting the rising global demand.

Global Pharmaceutical Manufacturing Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global pharmaceutical manufacturing market report based on molecule, drug development, formulation, route of administration, therapy area, prescription, age group, sales channel, and region:

• Molecule Outlook (Revenue, USD Billion, 2021 - 2033)

Biologics & Biosimilars (Large Molecules)

• Monoclonal Antibodies
• Vaccines
• Cell & Gene Therapy
• Others

Conventional Drugs (Small Molecules)

• Drug Development Outlook (Revenue, USD Billion, 2021 - 2033)

In-house

Outsource

• Formulation Outlook (Revenue, USD Billion, 2021 - 2033)

Tablets

Capsules

Injectable

Sprays

Suspensions

Powders

Other Formulations

• Route of Administration Outlook (Revenue, USD Billion, 2021 - 2033)

Oral

Topical

Parenteral

Inhalations

Other Routes of Administration

• Therapy Area Outlook (Revenue, USD Billion, 2021 - 2033)

Cardiovascular Diseases (CVDs)

Pain

Diabetes

Cancer

Respiratory Diseases

Other Diseases

• Prescription Outlook (Revenue, USD Billion, 2021 - 2033)

Prescription Medicines

Over-the-counter (OTC) Medicines

• Age Group Outlook (Revenue, USD Billion, 2021 - 2033)

Children & Adolescents

Adults

Geriatric

• Sales Channel Outlook (Revenue, USD Billion, 2021 - 2033)

Retail

Non-retail

• Regional Outlook (Revenue, USD Billion, 2021 - 2033)

North America

• U.S.
• Canada
• Mexico

Europe

• UK
• Germany
• France
• Italy
• Spain
• Sweden
• Norway
• Denmark

Asia Pacific

• China
• Japan
• India
• Australia
• Thailand
• South Korea

Latin America

• Brazil
• Argentina

Middle East and Africa

• Saudi Arabia
• South Africa
• UAE
• Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Molecule Type
  • 1.2.2. Drug Development Type
  • 1.2.3. Formulation
  • 1.2.4. Routes of Administration
  • 1.2.5. Therapy Area
  • 1.2.6. Prescription
  • 1.2.7. Age Group
  • 1.2.8. Sales Channel
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
• 1.6. Information Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Data Visualization
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
• 1.9. List of Secondary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Pharmaceutical Manufacturing Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Business Environment Analysis
  • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
    • 3.3.1.1. Supplier Power
    • 3.3.1.2. Buyer Power
    • 3.3.1.3. Substitution Threat
    • 3.3.1.4. Threat of New Entrants
    • 3.3.1.5. Competitive Rivalry
  • 3.3.2. PESTLE Analysis

Chapter 4. Pharmaceutical Manufacturing Market: Molecule Type Business Analysis

• 4.1. Molecule Type Market Share, 2025 & 2033
• 4.2. Molecule Type Segment Dashboard
• 4.3. Market Size & Forecasts and Trend Analysis, by Molecule Type, 2021 to 2033 (USD Billion)
• 4.4. Biologics & Biosimilars (Large Molecules)
  • 4.4.1. Biologics & Biosimilars (Large Molecules) Market Estimates & Forecasts 2021 to 2033 (USD Billion)
    • 4.4.1.1. Monoclonal Antibodies
      • 4.4.1.1.1. Monoclonal Antibodies Market Estimates & Forecasts 2021 to 2033 (USD Billion)
    • 4.4.1.2. Vaccines
      • 4.4.1.2.1. Vaccines Market Estimates & Forecasts 2021 to 2033 (USD Billion)
    • 4.4.1.3. Cell & Gene Therapy
      • 4.4.1.3.1. Cell & Gene Therapy Market Estimates & Forecasts 2021 to 2033 (USD Billion)
    • 4.4.1.4. Others
      • 4.4.1.4.1. Others Market Estimates & Forecasts 2021 to 2033 (USD Billion)
• 4.5. Conventional Drugs (Small Molecules)
  • 4.5.1. Conventional Drugs (Small Molecules) Market Estimates & Forecasts 2021 to 2033 (USD Billion)

Chapter 5. Pharmaceutical Manufacturing Market: Drug Development Business Analysis

• 5.1. Drug Development Market Share, 2025 & 2033
• 5.2. Drug Development Segment Dashboard
• 5.3. Market Size & Forecasts and Trend Analysis, by Drug Development, 2021 to 2033 (USD Billion)
• 5.4. Outsource
  • 5.4.1. Outsource Market Estimates & Forecasts, 2021 - 2033 (USD Billion)
• 5.5. In-house
  • 5.5.1. In-house Market Estimates & Forecasts, 2021 - 2033 (USD Billion)

Chapter 6. Pharmaceutical Manufacturing Market: Formulation Business Analysis

• 6.1. Formulation Market Share, 2025 & 2033
• 6.2. Formulation Segment Dashboard
• 6.3. Market Size & Forecasts and Trend Analysis, by Formulation, 2021 to 2033 (USD Billion)
• 6.4. Tablets
  • 6.4.1. Tablets Market Estimates & Forecasts, 2021 - 2033 (USD Billion)
• 6.5. Capsules
  • 6.5.1. Capsules Market Estimates & Forecasts, 2021 - 2033 (USD Billion)
• 6.6. Injectable
  • 6.6.1. Injectable Market Estimates & Forecasts, 2021 - 2033 (USD Billion)
• 6.7. Sprays
  • 6.7.1. Sprays Market Estimates & Forecasts, 2021 - 2033 (USD Billion)
• 6.8. Suspensions
  • 6.8.1. Suspensions Market Estimates & Forecasts, 2021 - 2033 (USD Billion)
• 6.9. Powders
  • 6.9.1. Powders Market Estimates & Forecasts, 2021 - 2033 (USD Billion)
• 6.10. Other
  • 6.10.1. Other Market Estimates & Forecasts, 2021 - 2033 (USD Billion)

Chapter 7. Pharmaceutical Manufacturing Market: Route of Administration Business Analysis

• 7.1. Route of Administration Market Share, 2025 & 2033
• 7.2. Route of Administration Segment Dashboard
• 7.3. Market Size & Forecasts and Trend Analysis, by Route of Administration, 2021 to 2033 (USD Billion)
• 7.4. Oral
  • 7.4.1. Oral Market Estimates & Forecasts, 2021 - 2033 (USD Billion)
• 7.5. Topical
  • 7.5.1. Topical Market Estimates & Forecasts, 2021 - 2033 (USD Billion)
• 7.6. Parenteral
  • 7.6.1. Parenteral Market Estimates & Forecasts, 2021 - 2033 (USD Billion)
• 7.7. Inhalations
  • 7.7.1. Inhalations Market Estimates & Forecasts, 2021 - 2033 (USD Billion)
• 7.8. Other
  • 7.8.1. Other Market Estimates & Forecasts, 2021 - 2033 (USD Billion)

Chapter 8. Pharmaceutical Manufacturing Market: Therapy Area Business Analysis

• 8.1. Therapy Area Market Share, 2025 & 2033
• 8.2. Therapy Area Segment Dashboard
• 8.3. Market Size & Forecasts and Trend Analysis, by Therapy Area, 2021 to 2033 (USD Billion)
• 8.4. Cardiovascular Diseases (CVDs)
  • 8.4.1. Cardiovascular Diseases (CVDs) Market Estimates & Forecasts, 2021 - 2033 (USD Billion)
• 8.5. Pain
  • 8.5.1. Pain Market Estimates & Forecasts, 2021 - 2033 (USD Billion)
• 8.6. Diabetes
  • 8.6.1. Diabetes Market Estimates & Forecasts, 2021 - 2033 (USD Billion)
• 8.7. Cancer
  • 8.7.1. Cancer Market Estimates & Forecasts, 2021 - 2033 (USD Billion)
• 8.8. Respiratory Diseases
  • 8.8.1. Respiratory Diseases Market Estimates & Forecasts, 2021 - 2033 (USD Billion)
• 8.9. Other
  • 8.9.1. Other Market Estimates & Forecasts, 2021 - 2033 (USD Billion)

Chapter 9. Pharmaceutical Manufacturing Market: Prescription Business Analysis

• 9.1. Prescription Market Share, 2025 & 2033
• 9.2. Prescription Segment Dashboard
• 9.3. Market Size & Forecasts and Trend Analysis, by Prescription, 2021 to 2033 (USD Billion)
• 9.4. Prescription Medicine
  • 9.4.1. Prescription Medicine Market Estimates & Forecasts, 2021 - 2033 (USD Billion)
• 9.5. Over-the-counter (OTC) Medicines
  • 9.5.1. Over-the-counter (OTC) Medicines Market Estimates & Forecasts, 2021 - 2033 (USD Billion)

Chapter 10. Pharmaceutical Manufacturing Market: Age Group Business Analysis

• 10.1. Age Group Market Share, 2025 & 2033
• 10.2. Age Group Segment Dashboard
• 10.3. Market Size & Forecasts and Trend Analysis, by Age Group, 2021 to 2033 (USD Billion)
• 10.4. Children & Adolescents
  • 10.4.1. Children & Adolescents Market Estimates & Forecasts, 2021 - 2033 (USD Billion)
• 10.5. Adult
  • 10.5.1. Adult Market Estimates & Forecasts, 2021 - 2033 (USD Billion)
• 10.6. Geriatric
  • 10.6.1. Geriatric Market Estimates & Forecasts, 2021 - 2033 (USD Billion)

Chapter 11. Pharmaceutical Manufacturing Market: Sales Channel Business Analysis

• 11.1. Sales Channel Market Share, 2025 & 2033
• 11.2. Sales Channel Segment Dashboard
• 11.3. Market Size & Forecasts and Trend Analysis, by Sales Channel, 2021 to 2033 (USD Billion)
• 11.4. Retail
  • 11.4.1. Retail Market Estimates & Forecasts, 2021 - 2033 (USD Billion)
• 11.5. Non-Retail
  • 11.5.1. Non-Retail Market Estimates & Forecasts, 2021 - 2033 (USD Billion)

Chapter 12. Pharmaceutical Manufacturing Market: Regional Estimates & Trend Analysis

• 12.1. Regional Market Share Analysis, 2025 & 2033
• 12.2. Regional Market Dashboard
• 12.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
• 12.4. North America
  • 12.4.1. North America Pharmaceutical Manufacturing Market Estimates & Forecasts, 2021 - 2033 (USD Billion)
  • 12.4.2. U.S.
    • 12.4.2.1. Key Country Dynamics
    • 12.4.2.2. Regulatory Framework
    • 12.4.2.3. U.S. Pharmaceutical Manufacturing Market Estimates & Forecasts, 2021 - 2033 (USD Billion)
  • 12.4.3. Canada
    • 12.4.3.1. Key Country Dynamics
    • 12.4.3.2. Regulatory Framework
    • 12.4.3.3. Canada Pharmaceutical Manufacturing Market Estimates & Forecasts, 2021 - 2033 (USD Billion)
  • 12.4.4. Mexico
    • 12.4.4.1. Key Country Dynamics
    • 12.4.4.2. Regulatory Framework
    • 12.4.4.3. Mexico Pharmaceutical Manufacturing Market Estimates & Forecasts, 2021 - 2033 (USD Billion)
• 12.5. Europe
  • 12.5.1. Europe Pharmaceutical Manufacturing Market Estimates & Forecasts, 2021 - 2033 (USD Billion)
  • 12.5.2. UK
    • 12.5.2.1. Key Country Dynamics
    • 12.5.2.2. Regulatory Framework
    • 12.5.2.3. UK Pharmaceutical Manufacturing Market Estimates & Forecasts, 2021 - 2033 (USD Billion)
  • 12.5.3. Germany
    • 12.5.3.1. Key Country Dynamics
    • 12.5.3.2. Regulatory Framework
    • 12.5.3.3. Germany Pharmaceutical Manufacturing Market Estimates & Forecasts, 2021 - 2033 (USD Billion)
  • 12.5.4. France
    • 12.5.4.1. Key Country Dynamics
    • 12.5.4.2. Regulatory Framework
    • 12.5.4.3. France Pharmaceutical Manufacturing Market Estimates & Forecasts, 2021 - 2033 (USD Billion)
  • 12.5.5. Italy
    • 12.5.5.1. Key Country Dynamics
    • 12.5.5.2. Regulatory Framework
    • 12.5.5.3. Italy Pharmaceutical Manufacturing Market Estimates & Forecasts, 2021 - 2033 (USD Billion)
  • 12.5.6. Spain
    • 12.5.6.1. Key Country Dynamics
    • 12.5.6.2. Regulatory Framework
    • 12.5.6.3. Spain Pharmaceutical Manufacturing Market Estimates & Forecasts, 2021 - 2033 (USD Billion)
  • 12.5.7. Denmark
    • 12.5.7.1. Key Country Dynamics
    • 12.5.7.2. Regulatory Framework
    • 12.5.7.3. Denmark Pharmaceutical Manufacturing Market Estimates & Forecasts, 2021 - 2033 (USD Billion)
  • 12.5.8. Sweden
    • 12.5.8.1. Key Country Dynamics
    • 12.5.8.2. Regulatory Framework
    • 12.5.8.3. Sweden Pharmaceutical Manufacturing Market Estimates & Forecasts, 2021 - 2033 (USD Billion)
  • 12.5.9. Norway
    • 12.5.9.1. Key Country Dynamics
    • 12.5.9.2. Regulatory Framework
    • 12.5.9.3. Norway Pharmaceutical Manufacturing Market Estimates & Forecasts, 2021 - 2033 (USD Billion)
• 12.6. Asia Pacific
  • 12.6.1. Asia Pacific Pharmaceutical Manufacturing Market Estimates & Forecasts, 2021 - 2033 (USD Billion)
  • 12.6.2. Japan
    • 12.6.2.1. Key Country Dynamics
    • 12.6.2.2. Regulatory Framework
    • 12.6.2.3. Japan Pharmaceutical Manufacturing Market Estimates & Forecasts, 2021 - 2033 (USD Billion)
  • 12.6.3. China
    • 12.6.3.1. Key Country Dynamics
    • 12.6.3.2. Regulatory Framework
    • 12.6.3.3. China Pharmaceutical Manufacturing Market Estimates & Forecasts, 2021 - 2033 (USD Billion)
  • 12.6.4. India
    • 12.6.4.1. Key Country Dynamics
    • 12.6.4.2. Regulatory Framework
    • 12.6.4.3. India Pharmaceutical Manufacturing Market Estimates & Forecasts, 2021 - 2033 (USD Billion)
  • 12.6.5. Australia
    • 12.6.5.1. Key Country Dynamics
    • 12.6.5.2. Regulatory Framework
    • 12.6.5.3. Australia Pharmaceutical Manufacturing Market Estimates & Forecasts, 2021 - 2033 (USD Billion)
  • 12.6.6. South Korea
    • 12.6.6.1. Key Country Dynamics
    • 12.6.6.2. Regulatory Framework
    • 12.6.6.3. South Korea Pharmaceutical Manufacturing Market Estimates & Forecasts, 2021 - 2033 (USD Billion)
  • 12.6.7. Thailand
    • 12.6.7.1. Key Country Dynamics
    • 12.6.7.2. Regulatory Framework
    • 12.6.7.3. Thailand Pharmaceutical Manufacturing Market Estimates & Forecasts, 2021 - 2033 (USD Billion)
• 12.7. Latin America
  • 12.7.1. Latin America Pharmaceutical Manufacturing Market Estimates & Forecasts, 2021 - 2033 (USD Billion)
  • 12.7.2. Brazil
    • 12.7.2.1. Key Country Dynamics
    • 12.7.2.2. Regulatory Framework
    • 12.7.2.3. Japan Pharmaceutical Manufacturing Market Estimates & Forecasts, 2021 - 2033 (USD Billion)
  • 12.7.3. Argentina
    • 12.7.3.1. Key Country Dynamics
    • 12.7.3.2. Regulatory Framework
    • 12.7.3.3. China Pharmaceutical Manufacturing Market Estimates & Forecasts, 2021 - 2033 (USD Billion)
• 12.8. Middle East and Africa
  • 12.8.1. Middle East and Africa Pharmaceutical Manufacturing Market Estimates & Forecasts, 2021 - 2033 (USD Billion)
  • 12.8.2. South Africa
    • 12.8.2.1. Key Country Dynamics
    • 12.8.2.2. Regulatory Framework
    • 12.8.2.3. South Africa Pharmaceutical Manufacturing Market Estimates & Forecasts, 2021 - 2033 (USD Billion)
  • 12.8.3. Saudi Arabia
    • 12.8.3.1. Key Country Dynamics
    • 12.8.3.2. Regulatory Framework
    • 12.8.3.3. Saudi Arabia Pharmaceutical Manufacturing Market Estimates & Forecasts, 2021 - 2033 (USD Billion)
  • 12.8.4. UAE
    • 12.8.4.1. Key Country Dynamics
    • 12.8.4.2. Regulatory Framework
    • 12.8.4.3. UAE Pharmaceutical Manufacturing Market Estimates & Forecasts, 2021 - 2033 (USD Billion)
  • 12.8.5. Kuwait
    • 12.8.5.1. Key Country Dynamics
    • 12.8.5.2. Regulatory Framework
    • 12.8.5.3. Kuwait Pharmaceutical Manufacturing Market Estimates & Forecasts, 2021 - 2033 (USD Billion)

Chapter 13. Competitive Landscape

• 13.1. Participant Overview
• 13.2. Company Market Position Analysis
• 13.3. Company Categorization
• 13.4. Strategy Mapping
• 13.5. Company Profiles/Listing
  • 13.5.1. F. Hoffmann-La Roche Ltd.
    • 13.5.1.1. Company Overview
    • 13.5.1.2. Financial Performance
    • 13.5.1.3. Product Benchmarking
    • 13.5.1.4. Strategic Initiatives
  • 13.5.2. Novartis AG
    • 13.5.2.1. Company Overview
    • 13.5.2.2. Financial Performance
    • 13.5.2.3. Product Benchmarking
    • 13.5.2.4. Strategic Initiatives
  • 13.5.3. GSK plc
    • 13.5.3.1. Company Overview
    • 13.5.3.2. Financial Performance
    • 13.5.3.3. Product Benchmarking
    • 13.5.3.4. Strategic Initiatives
  • 13.5.4. Pfizer, Inc.
    • 13.5.4.1. Company Overview
    • 13.5.4.2. Financial Performance
    • 13.5.4.3. Product Benchmarking
    • 13.5.4.4. Strategic Initiatives
  • 13.5.5. Merck & Co., Inc.
    • 13.5.5.1. Company Overview
    • 13.5.5.2. Financial Performance
    • 13.5.5.3. Product Benchmarking
    • 13.5.5.4. Strategic Initiatives
  • 13.5.6. AstraZeneca
    • 13.5.6.1. Company Overview
    • 13.5.6.2. Financial Performance
    • 13.5.6.3. Product Benchmarking
    • 13.5.6.4. Strategic Initiatives
  • 13.5.7. Johnson & Johnson
    • 13.5.7.1. Company Overview
    • 13.5.7.2. Financial Performance
    • 13.5.7.3. Product Benchmarking
    • 13.5.7.4. Strategic Initiatives
  • 13.5.8. Sanofi SA
    • 13.5.8.1. Company Overview
    • 13.5.8.2. Financial Performance
    • 13.5.8.3. Product Benchmarking
    • 13.5.8.4. Strategic Initiatives
  • 13.5.9. Eli Lilly and Company
    • 13.5.9.1. Company Overview
    • 13.5.9.2. Financial Performance
    • 13.5.9.3. Product Benchmarking
    • 13.5.9.4. Strategic Initiatives
  • 13.5.10. AbbVie, Inc.
    • 13.5.10.1. Company Overview
    • 13.5.10.2. Financial Performance
    • 13.5.10.3. Product Benchmarking
    • 13.5.10.4. Strategic Initiatives
  • 13.5.11. Thermo Fisher Scientific, Inc.
    • 13.5.11.1. Company Overview
    • 13.5.11.2. Financial Performance
    • 13.5.11.3. Product Benchmarking
    • 13.5.11.4. Strategic Initiatives
  • 13.5.12. Wuxi Apptec
    • 13.5.12.1. Company Overview
    • 13.5.12.2. Financial Performance
    • 13.5.12.3. Product Benchmarking
    • 13.5.12.4. Strategic Initiatives
  • 13.5.13. Samsung Biologics
    • 13.5.13.1. Company Overview
    • 13.5.13.2. Financial Performance
    • 13.5.13.3. Product Benchmarking
    • 13.5.13.4. Strategic Initiatives
  • 13.5.14. FUJIFILM Biotechnologies
    • 13.5.14.1. Company Overview
    • 13.5.14.2. Financial Performance
    • 13.5.14.3. Product Benchmarking
    • 13.5.14.4. Strategic Initiatives
  • 13.5.15. Lonza
    • 13.5.15.1. Company Overview
    • 13.5.15.2. Financial Performance
    • 13.5.15.3. Product Benchmarking
    • 13.5.15.4. Strategic Initiatives
  • 13.5.16. Catalent, Inc.
    • 13.5.16.1. Company Overview
    • 13.5.16.2. Financial Performance
    • 13.5.16.3. Product Benchmarking
    • 13.5.16.4. Strategic Initiatives
  • 13.5.17. Jubilant Pharmova Limited
    • 13.5.17.1. Company Overview
    • 13.5.17.2. Financial Performance
    • 13.5.17.3. Product Benchmarking
    • 13.5.17.4. Strategic Initiatives